Program length (45 minutes)
- Welcome and Introduction
- Case-Based Presentation
- Discussion and Audience Question and Answer Session
Philip N. Newsome, PhD, FRCPE
Professor of Hepatology
University of Birmingham
Birmingham, United Kingdom
The goal of this activity is to improve participants’ competence in identifying and managing patients with or at risk for NASH and in knowledge of emerging NASH therapies and diagnostic tests.
This program is intended for gastroenterologists, hepatologists, endocrinologists, and other healthcare providers who care for patients with or at risk for NASH.
- Evaluate risk and apply appropriate methodology to characterize NAFLD and diagnose NASH in individual patients
- Apply best practices in the management of patients with NAFLD based on evolving data on lifestyle modification and medical treatment
- Critically evaluate data on emerging therapies for NASH, including evidence of reversal of fibrosis, risks and benefits, and their potential utility in the treatment of patients with NASH
- Demonstrate an understanding of clinical trial design and evaluation of endpoints in the setting of NAFLD/NASH
Physician Continuing Medical Education
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the American Gastroenterological Association and Clinical Care Options, LLC. American Gastroenterological Association is accredited by the ACCME to provide continuing medical education for physicians.
American Gastroenterological Association designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
In accordance with the ACCME’s Standards for Commercial Support of Continuing Medical Education, all faculty and planning partners must disclose any financial relationship(s) or other relationship(s) held within the past 12 months. The AGA Institute implements a mechanism to identify and resolve all conflicts of interest prior to delivering the educational activity to learners.
Disclosure of Conflicts of Interest
AGA requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. AGA is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.